Terence R. Jones - Concepedia

Author

Terence R. Jones

Also Known As

Jones, T, T R Jones, T. Jones, T. R. JONES, T. R. Jones, T.R. Jones, TERENCE R. JONES, Talfourd Jones, Terence Jones, Terence R Jones

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Institute of Cancer Research Angstrom Designs (United States)The University of Texas MD Anderson Cancer Center Yonsei University University of California San Diego

About

Terence R. Jones is an author at Institute of Cancer Research specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	780
2	Biochemistry	6	6	256
3	Natural Sciences	5	5	131
4	Engineering	1	1	24
5	Health Sciences	1	1	102

Terence R. Jones

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
A potent antitumour quinazoline inhibitor of thymidylate synthetase: Synthesis, biological properties and therapeutic results in mice Terence R. Jones, A H Calvert, Ann L. Jackman, European Journal of Cancer (1965) Antiparasitic AgentMedicineMolecular BiologyThymidylate SynthetaseBiological Properties	1981	239
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. A H Calvert, D Alison, S. J. Harland, Journal of Clinical Oncology PathologyPharmacotherapyPharmaceutical ChemistryPre-clinical PharmacologyDrug Resistance	1986	102
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis <i>in vivo</i> in combination with cisplatin Kazuhiko Mishima, Andrew P. Mazar, Allen M. Gown, Proceedings of the National Academy of Sciences Peptide ScienceCancer BiologyGliomaTumor BiologyNeuro-oncology	2000	90
Transcriptional Induction of the Urokinase Receptor Gene by a Constitutively Active Src Heike Allgayer, Heng Wang, Gary E. Gallick, Journal of Biological Chemistry	1999	73
Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C-2 position Leslie R. Hughes, Ann L. Jackman, J.W. Oldfield, Journal of Medicinal Chemistry	1990	73
Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial Anna Berkenblit, Ursula A. Matulonis, Joan F. Kroener, Gynecologic Oncology Urokinase Plasminogen ActivatorAdvanced Gynecologic CancerMedicineGynecologyPeptide Therapeutic	2005	66
Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency Terence R. Jones, Timothy J. Thornton, Anthony Flinn, Journal of Medicinal Chemistry	1989	61
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group Rashmi Ramasubbaiah, Susan M. Perkins, Jeanne M. Schilder, Gynecologic Oncology Hoosier Oncology GroupWeekly TopotecanMedicineGynecologyRecurrent Ovarian Cancer	2011	53
A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death <i>in vivo</i> Yongjing Guo, Abd Al‐Roof Higazi, Ani Arakelian, The FASEB Journal	2000	48
Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistance A H Calvert, Terence R. Jones, P J Dady, European Journal of Cancer (1965) Pharmaceutical ChemistryBiochemistryMedicinePharmacotherapyBiological Studies	1980	43

Page 1